Antigen News and Research

RSS

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Healthcare system perceptions predict PSA screening uptake

Study findings suggest that African–American and Afro–Caribbean men who have poor perceptions or experiences of their healthcare system are less likely to have prostate-specific antigen screening than those with positive healthcare experiences.

25 Jul 2012

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

White blood cells called neutrophils, which are the first line of defense against infection, play an unexpected role by boosting antibody production, according to research led by Mount Sinai School of Medicine. The findings suggest neutrophils have multiple roles within the immune system and function at levels previously unknown to the scientific community. The research, published in Nature Immunology, provides groundbreaking insight into possible new approaches in vaccine development for blood-borne infections and HIV.

25 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

Estrogen may mediate low incidence of HCC in women

Study findings suggest that estrogen may have a suppressive effect on hepatocellular carcinoma, potentially explaining its lower incidence in women.

18 Jul 2012

Thermo Fisher Scientific signs definitive agreement to acquire One Lambda

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire One Lambda, the leader in transplant diagnostics, for $925 million in cash, subject to a post-closing adjustment.

From Thermo Fisher Scientific Inc. 17 Jul 2012

New CD141hi DC subset plays a critical role in activating immune response against pathogens

Scientists at A*STAR's Singapore Immunology Network (SIgN), in collaboration with Newcastle University, UK, the Singapore Institute of Clinical Sciences and clinicians from multiple hospitals in Singapore, have identified a new subset of dendritic cells (DCs) in human peripheral tissue which have a critical role in activating our immune response against harmful pathogens.

17 Jul 2012

Potassium channel KIR4.1 clue to multiple sclerosis

The potassium channel KIR4.1 is a potential immune target in certain patients with multiple sclerosis, report researchers in TheNew England Journal of Medicine.

12 Jul 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

Researchers develop new silk-based stabilizer for vaccines and antibiotics

Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit.

10 Jul 2012

Scientists develop novel anticancer drug designed to travel through the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins.

10 Jul 2012

Human immune response: TCD scientists make breakthrough which could lead to new drug therapies

A team of researchers at Trinity College Dublin’s School of Medicine has gained new insights into a protein in the human immune system that plays a key role in the protective response to infection and inflammation. The research findings have just been published in the internationally renowned peer-reviewed Journal of Biological Chemistry.

9 Jul 2012

Merck, PDS Biotechnology enter licensing agreement for Versamune

PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

9 Jul 2012

New vaccine candidate against leading cause of hospital-acquired infections

Researchers at Brigham and Women's Hospital (BWH) have discovered a new vaccine candidate for the bacterium Pseudomonas aeruginosa taking advantage of a new mechanism of immunity.

7 Jul 2012

FDC precursor cells exist in the wall of blood vessels

Chronic inflammatory conditions are extremely common diseases in humans and in the entire animal kingdom. Both in autoimmune diseases and pathogen-caused diseases, the inflamed areas are rapidly colonized by antibody producing B lymphocytes - which organize themselves in highly structured areas called "lymphoid follicles".

6 Jul 2012

Antigen News and Research

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Healthcare system perceptions predict PSA screening uptake

Insight into possible new approaches in vaccine development for blood-borne infections and HIV

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

BioDiem presents positive findings of their eye disease drug at international conference

New CHAIT initiative on development of novel immunological therapeutic interventions

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Estrogen may mediate low incidence of HCC in women

Thermo Fisher Scientific signs definitive agreement to acquire One Lambda

New CD141hi DC subset plays a critical role in activating immune response against pathogens

Potassium channel KIR4.1 clue to multiple sclerosis

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Researchers develop new silk-based stabilizer for vaccines and antibiotics

Scientists develop novel anticancer drug designed to travel through the bloodstream

Human immune response: TCD scientists make breakthrough which could lead to new drug therapies

Merck, PDS Biotechnology enter licensing agreement for Versamune

New vaccine candidate against leading cause of hospital-acquired infections

FDC precursor cells exist in the wall of blood vessels

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News